Recent News

• 02.09.2026 - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
• 01.23.2026 - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
• 01.21.2026 - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
• 01.15.2026 - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
• 01.13.2026 - Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
• 01.12.2026 - Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
• 01.09.2026 - Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
• 12.10.2025 - Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Recent Filings

• 02.09.2026 - 8-K Current report
• 01.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.23.2026 - EX-99.1 EX-99.1
• 01.23.2026 - 8-K Current report
• 01.21.2026 - 8-K Current report
• 01.21.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.21.2026 - EX-99.1 EX-99.1
• 01.15.2026 - EX-99.1 EX-99.1
• 01.15.2026 - 8-K Current report
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities